Retatrutide Dosage: What the Trials Actually Used
Last updated May 19, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Back to the Retatrutide Hub · See also: vs Tirzepatide · FDA approval status
Retatrutide is investigational and not FDA approved, so it has no official dose, label, or prescribing information. Everything below describes how the drug was dosed in clinical trials under medical supervision, provided to help you read the research — not as instructions for use. Self-administering an unapproved drug carries unknown and potentially serious risks.
The short version
Retatrutide is given as a once-weekly subcutaneous injection. Because its half-life is roughly six days, a weekly cadence keeps drug levels relatively steady. The dose is escalated slowly over months to a target, with the largest weight-loss effects seen at the 8–12 mg range. The two key reasons the dose climbs gradually rather than starting high: minimizing gastrointestinal side effects, and carefully balancing the glucagon-receptor component that distinguishes retatrutide from tirzepatide and semaglutide.
Phase 2 obesity titration
The pivotal Phase 2 obesity trial assigned participants to target doses of 1, 4, 8, or 12 mg weekly, reaching those targets through a stepped escalation over roughly the first few months. A representative path to the 12 mg target looked like a doubling sequence — for example 2 mg → 4 mg → 8 mg → 12 mg — with several weeks at each step before moving up.
| Target dose | Typical escalation | Cadence | Mean weight loss (48 wks) |
|---|---|---|---|
| 1 mg | start / hold | Weekly SubQ | ~8.7% |
| 4 mg | 2 → 4 mg | Weekly SubQ | ~17.1% |
| 8 mg | 2 → 4 → 8 mg | Weekly SubQ | ~22.8% |
| 12 mg | 2 → 4 → 8 → 12 mg | Weekly SubQ | ~24.2% |
→ Plan this schedule in the GLP-1 Titration Planner — pick a target dose and start date for a dated, week-by-week plan and an escalation chart.
The pattern is clearly dose-dependent: higher targets produced more weight loss, with 8 mg and 12 mg delivering the bulk of the effect. About 93% of people on 12 mg lost at least 15% of their body weight.
TRIUMPH-4 (Phase 3) doses
The first Phase 3 readout, TRIUMPH-4, narrowed to the two highest investigational doses — 9 mg and 12 mg — over 68 weeks in adults with obesity and knee osteoarthritis. The 12 mg dose produced up to 28.7% mean weight loss, the largest reported in any obesity trial. Both doses followed a gradual titration to target before the maintenance phase.
Why the escalation is slow
Two forces drive the cautious ramp:
1. Gastrointestinal tolerance. Nausea, diarrhea, constipation, and vomiting are most intense when the dose first rises. Stepping up slowly gives the gut time to adapt, which is the same logic behind semaglutide and tirzepatide titration.
2. The glucagon balance. Retatrutide's third receptor — glucagon — adds energy expenditure and fat oxidation, but glucagon can also nudge blood sugar upward if unopposed. Slow titration lets the GLP-1/GIP glucose-lowering effects keep pace, so the net metabolic effect stays favorable.
There is also a counterintuitive lesson from TRIUMPH-4: some participants discontinued because of excessive or overly rapid weight loss, particularly those starting at lower BMIs. More and faster is not automatically better — which is exactly why dosing in a real program is individualized and supervised.
Reconstitution basics
Retatrutide studied in trials is supplied as a prepared injectable; the lyophilized "research" powders sold online require reconstitution with bacteriostatic water before they can be measured into a syringe — a process with real margin for error. The arithmetic (vial strength ÷ diluent volume = concentration; desired dose ÷ concentration = volume to draw) trips up a lot of people. If you are studying that math, our tools handle it precisely:
→ Reconstitution Calculator — converts vial strength + BAC water volume into an exact syringe draw, with a visual syringe.
→ Half-Life Visualizer — model how retatrutide's ~6-day half-life shapes drug levels across a weekly cycle.
Remember: a calculator can do the arithmetic, but it cannot make an unapproved compound safe, sterile, or correctly identified. Those remain unknowns outside a trial.
Frequently asked questions
What is the "maximum" retatrutide dose?
In trials, 12 mg weekly was the highest dose studied and produced the greatest weight loss. There is no approved maximum because the drug isn't approved.
How long until it "works"?
Weight loss appeared early in trials — measurable within the first few weeks — and continued throughout the 48–68 week studies. Trials run long because the effect keeps building over many months.
Can the dose be too high?
Yes — TRIUMPH-4 saw discontinuations tied to excessive weight loss in lower-BMI participants. This is one reason dosing is meant to be individualized and supervised, not maximized by default.
Sources
- Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514–526.
- Eli Lilly & Company. TRIUMPH-4 Phase 3 topline results. News release, December 11, 2025.
- ClinicalTrials.gov — TRIUMPH program registrations.
Medical disclaimer: Education only, not medical advice. Retatrutide is investigational and not approved for use. Do not self-administer; consult a licensed clinician.